{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:35:48Z","timestamp":1794627348776,"version":"4.9.1"},"reference-count":172,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["mAbs"],"published-print":{"date-parts":[[2026,12,31]]},"DOI":"10.1080\/19420862.2026.2614669","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:07:07Z","timestamp":1768986427000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":41,"title":["Antibodies to watch in 2026"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1909-5957","authenticated-orcid":false,"given":"Silvia","family":"Crescioli","sequence":"first","affiliation":[{"name":"Business Intelligence","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-2195","authenticated-orcid":false,"given":"H\u00e9l\u00e8ne","family":"Kaplon","sequence":"additional","affiliation":[{"name":"Therapeutic Area Oncology","place":["Gif-Sur-Yvette, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2736-9268","authenticated-orcid":false,"given":"Alicia","family":"Chenoweth","sequence":"additional","affiliation":[{"name":"School of Basic & Medical Biosciences","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9288-971X","authenticated-orcid":false,"given":"Yu-Shin","family":"Hsu","sequence":"additional","affiliation":[{"name":"Hanson Wade Group","place":["London, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4740-7666","authenticated-orcid":false,"given":"Kieran","family":"Pinto","sequence":"additional","affiliation":[{"name":"Strategic CI Division","place":["Cambridge, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7581-1487","authenticated-orcid":false,"given":"Vaishali","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis School of Medicine","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0400-1951","authenticated-orcid":false,"given":"Janice M.","family":"Reichert","sequence":"additional","affiliation":[{"name":"Business Intelligence","place":["Framingham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"e_1_3_4_2_1","unstructured":"Taylor & Francis. Antibodies to watch collection. mAbs. 2025 [accessed 2025 Nov 16]. https:\/\/www.tandfonline.com\/journals\/kmab20\/collections\/antibodies-to-watch."},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02267-y"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-025-00102-1"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-025-00185-w"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2024.07.001"},{"key":"e_1_3_4_7_1","unstructured":"CSL. Health Canada has authorized CSL\u2019s ANDEMBRY\u00ae (garadacimab) as once-monthly treatment for hereditary angioedema (HAE). 2025 [accessed 2025 Nov 10]. https:\/\/www.cslbehring.ca\/news\/2025\/health-canada-has-authorized-csl-andembry."},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00350-1"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16351"},{"key":"e_1_3_4_10_1","unstructured":"InflaRx N.V. Inflarx receives European Commission approval for GOHIBIC\u00ae (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome (ARDS). 2025 [accessed 2025 Nov 10]. https:\/\/www.inflarx.de\/Home\/Investors\/Press-Releases\/Press-Release~2025-01-InflaRx-Receives-European-Commission-Approval-for-GOHIBIC\u2014vilobelimab\u2013for-the-Treatment-of-SARS-CoV-2-Induced-Acute-Respiratory-Distress-Syndrome\u2013ARDS-~.html."},{"key":"e_1_3_4_11_1","unstructured":"European Medicines Agency. Gohibic. [accessed 2025 Nov 10]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/gohibic."},{"key":"e_1_3_4_12_1","unstructured":"European Medicines Agency. Lynozyfic. [accessed 2025 Dec 1]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynozyfic."},{"key":"e_1_3_4_13_1","unstructured":"Regeneron Pharmaceuticals Inc. Lynozyfic\u2122 (linvoseltamab-gcpt) receives FDA accelerated approval for treatment of relapsed or refractory multiple myeloma. 2025 [accessed 2025 Nov 11]. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/lynozyfictm-linvoseltamab-gcpt-receives-fda-accelerated-approval."},{"key":"e_1_3_4_14_1","unstructured":"Food and Drug Administration. Linvoseltamab NDA\/BLA multi-disciplinary review and evaluation. 2024 [accessed 2025 Dec 3]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/761400Orig1s000MultidisciplineR.pdf."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2461191"},{"key":"e_1_3_4_16_1","unstructured":"Johnson & Johnson. Johnson & Johnson receives FDA approval for IMAAVYTM (nipocalimab-aahu) a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG). 2025 [accessed 2025 Nov 11]. https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-receives-fda-approval-for-imaavytm-nipocalimab-aahu-a-new-fcrn-blocker-offering-long-lasting-disease-control-in-the-broadest-population-of-people-living-with-generalized-myasthenia-gravis-gmg."},{"key":"e_1_3_4_17_1","unstructured":"Johnson & Johnson. Johnson & Johnson receives European Commission approval of IMAAVY\u00ae\u25bc (nipocalimab) a new FcRn blocker offering sustained disease control in a broad population of people living with generalised myasthenia gravis (gMG). 2025 [accessed 2025 Dec 3]. https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-receives-european-commission-approval-of-imaavy-nipocalimab-a-new-fcrn-blocker-offering-sustained-disease-control-in-a-broad-population-of-people-living-with-generalised-myasthenia-gravis-gmg."},{"key":"e_1_3_4_18_1","unstructured":"US Food and Drug Administration. Prescribing information: ImaavyTM (nipocalimab-aahu) injection for intravenous use. 2025 [accessed 2025 Nov 12]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761430s000lbl.pdf."},{"key":"e_1_3_4_19_1","unstructured":"Johnson & Johnson. Johnson & Johnson announces first head-to-head study comparing IMAAVY\u2122 with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM annual meeting. 2025 [accessed 2025 Nov 11]. https:\/\/www.jnj.com\/media-center\/press-releases\/johnson-johnson-announces-first-head-to-head-study-comparing-imaavy-with-an-alternative-fcrn-blocker-in-generalized-myasthenia-gravis-gmg-at-aanem-annual-meeting."},{"key":"e_1_3_4_20_1","unstructured":"US Food and Drug Administration. Fda grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-met protein overexpression. 2025 [accessed 2025 Nov 12]. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression."},{"key":"e_1_3_4_21_1","unstructured":"Merck US. Fda approves Merck\u2019s Enflonsia\u2122 (clesrovimab-cfor) for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants born during or entering their first RSV season. 2025 [accessed 2025 Nov 12]. https:\/\/www.merck.com\/news\/u-s-fda-approves-mercks-enflonsia-clesrovimab-cfor-for-prevention-of-respiratory-syncytial-virus-rsv-lower-respiratory-tract-disease-in-infants-born-during-or-entering-their-fir\/."},{"key":"e_1_3_4_22_1","unstructured":"European Medicines Agency. Enflonsia\u00ae (clesrovimab). 2025 [accessed 2025 Dec 3]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/enflonsia."},{"key":"e_1_3_4_23_1","unstructured":"US Food and Drug Administration. Prescribing information: Enflonsia\u2122 (clesrovimab-cfor) injection for intramuscular use. 2025 [accessed 2025 Nov 12]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/761432s000lbl.pdf."},{"key":"e_1_3_4_24_1","unstructured":"Otsuka Pharmaceutical Co. Ltd.. Otsuka receives FDA accelerated approval for VOYXACT\u00ae (sibeprenlimab-szsi) for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. 2025 [accessed 2025 Nov 26]. https:\/\/www.otsuka-us.com\/news\/otsuka-receives-fda-accelerated-approval-voyxactr-sibeprenlimab-szsi-reduction-proteinuria."},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305635"},{"key":"e_1_3_4_26_1","unstructured":"Otsuka Pharmaceutical Co. Ltd.. Otsuka sibeprenlimab phase 3 data show a statistically significant and clinically meaningful proteinuria reduction for the treatment of immunoglobulin A nephropathy (IgAN). 2025 [accessed 2025 Oct 8]. https:\/\/www.otsuka-us.com\/news\/otsuka-sibeprenlimab-phase-3-data-show-statistically-significant-and-clinically-meaningful."},{"key":"e_1_3_4_27_1","unstructured":"GSK plc. Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps. 2025 [accessed 2025 Dec 16]. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/exdensur-depemokimab-approved-in-the-uk-for-treatment-of-asthma-with-type-2-inflammation-and-chronic-rhinosinusitis-with-nasal-polyps\/."},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406673"},{"key":"e_1_3_4_29_1","unstructured":"GSK plc. GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps. 2024 [accessed 2025 Oct 9]. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/gsk-announces-positive-phase-iii-results-from-anchor-trials\/."},{"key":"e_1_3_4_30_1","unstructured":"Omeros Corporation. FDA approves omeros\u2019 YARTEMLEA\u00ae \u2013 first and only therapy indicated for TA-TMA. 2025. [accessed 2025 Dec 26]. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-corporation-reports-third-quarter-2025-financial-results."},{"key":"e_1_3_4_31_1","unstructured":"Omeros Corporation. Omeros submits narsoplimab marketing authorization application to the European Medicines Agency for the treatment of TA-TMA. 2025 [accessed 2025 Oct 7]. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-submits-narsoplimab-marketing-authorization-application."},{"key":"e_1_3_4_32_1","unstructured":"Omeros Corporation. Omeros announces update on statistical analysis of narsoplimab pivotal trial primary endpoint. 2025 [accessed 2025 Oct 7]. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-announces-update-statistical-analysis-narsoplimab-pivotal."},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.70044"},{"key":"e_1_3_4_34_1","unstructured":"Omeros Corporation. Omeros announces robust results for narsoplimab expanded access program in TA-TMA. 2025 [accessed 2025 Oct 7]. https:\/\/investor.omeros.com\/news-releases\/news-release-details\/omeros-announces-robust-results-narsoplimab-expanded-access."},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02199-5"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.07.035"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.09.012"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvaf155"},{"key":"e_1_3_4_39_1","unstructured":"Patsnap. Finotonlimab: a promising anti-PD-1 antibody for solid tumors. 2025 [accessed 2025 Nov 12]. https:\/\/synapse.patsnap.com\/blog\/finotonlimab-a-promising-anti-pd-1-antibody-for-solid-tumors."},{"key":"e_1_3_4_40_1","unstructured":"Sinocelltech Ltd. From head and neck squamous cell carcinoma to liver cancer! Anyouping\u00ae approved for two major indications. 2025 [accessed 2025 Dec 2]. https:\/\/www.sinocelltech.com\/Detail\/desc\/pid\/23\/sid\/486.html."},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03110-7"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02333-5"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-1042"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03791-8"},{"key":"e_1_3_4_45_1","unstructured":"Zhuhai Trinomab Pharmaceuticals Co. Ltd. Global breakthrough: Sintetol\u00ae\u2014next-generation tetanus prophylaxis agent\u2014approved for marketing in China. 2025 [accessed 2025 Nov 13]. https:\/\/www.trinomab.com\/en-us\/info\/499.html#:~:text=Sintetol%C2%AE%20has%20received%20regulatory US%20FDA%20in%20August%202022."},{"key":"e_1_3_4_46_1","unstructured":"Akeso Inc.. Akeso\u2019s ebdarokimab (IL - 12\/IL - 23 dual - targeted monoclonal antibody) approved in China for moderate - to - severe plaque psoriasis. 2025 [accessed 2025 Oct 28]. https:\/\/www.akesobio.com\/en\/media\/akeso-news\/250418\/."},{"key":"#cr-split#-e_1_3_4_47_1.1","unstructured":"Zhang J l Z Wang G Xia Y Wang M Li B. Long-term safety and efficacy of ebdarokimab in patients with moderate to severe plaque psoriasis: results from a single arm open label multicenter phase III clinical study. 2024 European Academy of Dermatology & Venereology Congress 2024 Sep 25-28 Amsterdam"},{"key":"#cr-split#-e_1_3_4_47_1.2","unstructured":"Abst. 982. [accessed 2025 Oct 28]. https:\/\/s3.eu-central-1.amazonaws.com\/m-anage.com.storage.eadv\/abstracts_congress_2024\/42456.pdf."},{"key":"e_1_3_4_48_1","unstructured":"Hengrui Pharma. China\u2019s HER2-targeted ADC trastuzumab rezetecan gains NMPA approval for HER2-mutant NSCLC. 2025 [accessed 2025 Oct 28]. https:\/\/www.prnewswire.com\/news-releases\/chinas-her2-targeted-adc-trastuzumab-rezetecan-gains-nmpa-approval-for-her2-mutant-nsclc-302468141.html."},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00012-9"},{"key":"e_1_3_4_50_1","unstructured":"Hengrui Pharma. Hengrui Pharma and Glenmark Pharmaceuticals enter exclusive license agreement for HER2 ADC trastuzumab rezetecan (SHR-A1811). 2025 [accessed 2025 Oct 28]. https:\/\/www.hengrui.com\/en\/media\/detail-852.html."},{"key":"e_1_3_4_51_1","unstructured":"Simcere Zaiming Pharmaceutical Co. Ltd.. Suvemcitug met primary endpoint in phase 3 clinical trial in China. 2024 [accessed 2025 Oct 25]. https:\/\/www.simcere.com\/en\/news\/detail.aspx?mtt=417."},{"key":"e_1_3_4_52_1","unstructured":"Simcere Pharmaceutical Group Limited. Approval for marketing of Enzeshu\u00ae in China by the National Medical Products Administration. 2025 [accessed 2025 Oct 28]. https:\/\/www.hkexnews.hk\/listedco\/listconews\/sehk\/2025\/0703\/2025070300360.pdf."},{"key":"e_1_3_4_53_1","unstructured":"Changchun GeneScience Pharmaceuticals Co. Ltd. Firsekibart approved with 87% reduction in gout recurrence over 6 months. 2025 [accessed 2025 Nov 13]. https:\/\/www.genscigroup.com\/en\/news\/media\/175."},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06072-7"},{"key":"e_1_3_4_55_1","doi-asserted-by":"crossref","unstructured":"Xue Y Chu T Hu J Gou W Zhang N Li J Yu J Li R Qian L Duan X et al. Efficacy and safety of firsekibart in patients with acute gouty arthritis with eGFR less than 60 mL\/min per 1.73 m2: post hoc analysis of 24-week data. 2025 accessed 2025 Nov 13. doi: 10.1681\/ASN.20251b4pt2q8.","DOI":"10.1681\/ASN.20251b4pt2q8"},{"key":"e_1_3_4_56_1","unstructured":"Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.. Core product trastuzumab botidotin approved for marketing by the National Medical Products Administration for 2L+ HER2+ BC. 2025 [accessed 2025 Oct 21]. https:\/\/ir-upload.realxen.net\/iis\/6990\/uploads\/iis\/2025\/11882363-0.PDF."},{"key":"e_1_3_4_57_1","unstructured":"Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.. Kelun-biotech presents positive phase 3 data for trastuzumab botidotin compared to T-DM1 at 2025 ESMO. 2025 [accessed 2025 Oct 21]. https:\/\/www.prnewswire.com\/news-releases\/kelun-biotech-presents-positive-phase-3-data-for-trastuzumab-botidotin-compared-to-t-dm1-at-2025-esmo-302588701.html."},{"key":"e_1_3_4_58_1","unstructured":"Lepu Biopharma Co. Ltd.. Interim report 2025. [accessed 2025 Oct 10]. https:\/\/en.lepubiopharma.com\/upload\/listedco\/listconews\/sehk\/2025\/0919\/2025091900516.pdf."},{"key":"e_1_3_4_59_1","unstructured":"Lepu Biopharma Co. Ltd.. Marketing approval obtained in China for meiyouheng (becotatug vedotin injection). 2025 [accessed 2025 Dec 3]. https:\/\/en.lepubiopharma.com\/new\/213.html."},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA6005"},{"key":"e_1_3_4_61_1","unstructured":"Innovent Biologics Inc. China\u2019s first domestic IL-23p19 monoclonal antibody: Innovent\u2019s PECONDLE\u00ae (picankibart injection) received NMPA approval. 2025 [accessed 2025 Dec 5]. https:\/\/www.prnewswire.com\/news-urlreleaseurls\/chinas-first-domestic-il-23p19-monoclonal-antibody-innovents-pecondle-picankibart-injection-received-nmpa-approval-302627980.html."},{"key":"e_1_3_4_62_1","unstructured":"Innovent Biologics Inc. Innovent announces picankibart (IBI112) achieved primary endpoints in a phase 3 clinical trial in treating moderate to severe plaque psoriasis and plans to submit NDA to the NMPA. 2024 [accessed 2025 Nov 7]. https:\/\/en.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=450."},{"key":"e_1_3_4_63_1","unstructured":"Innovent Biologics Inc. Innovent announces phase 2 clinical study of picankibart (IBI112) in Chinese patients with ulcerative colitis met primary endpoint. 2024 [accessed 2025 Oct 6]. https:\/\/en.innoventbio.com\/InvestorsAndMedia\/PressReleaseDetail?key=488."},{"key":"e_1_3_4_64_1","unstructured":"SFJ Pharmaceuticals. Fda has accepted a bla for bentracimab the first and only ticagrelor reversal agent for filing and priority review. 2024 [accessed 2025 Oct 9]. https:\/\/www.sfj-pharma.com\/fda-has-accepted-a-bla-for-bentracimab-the-first-and-only-ticagrelor-reversal-agent-for-filing-and-priority-review\/."},{"key":"e_1_3_4_65_1","unstructured":"SERB Pharmaceuticals. Sfj Pharmaceuticals and Serb Pharmaceuticals present positive final results from pivotal Phase 3 REVERSE-IT trial of Bentracimab for the reversal of antiplatelet effects of ticagrelor in patients requiring surgery or experiencing major bleeding. 2025 [accessed 2025 Nov 5]. https:\/\/serb.com\/news\/sfj-pharmaceuticals-and-serb-pharmaceuticals-present-positive-final-results-from-pivotal-phase-3-reverse-it-trial-of-bentracimab-for-the-reversal-of-antiplatelet-effects-of-ticagrelor-in-patients-requ\/."},{"key":"e_1_3_4_66_1","unstructured":"Scholar Rock. Fda issues complete response letter (CRL) for Apitegromab as a treatment for patients with spinal muscular atrophy (SMA) solely related to observations identified at Catalent Indiana LLC fill-finish facility. 2025 [accessed 2025 Oct 7]. https:\/\/investors.scholarrock.com\/news-releases\/news-release-details\/fda-issues-complete-response-letter-crl-apitegromab-treatment."},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209151"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1419791"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00225-X"},{"key":"e_1_3_4_70_1","unstructured":"Novo Nordisk. Novo Nordisk submits Biologics license application (BLA) to FDA for Mim8; an investigational prophylaxis treatment for people living with hemophilia A with or without inhibitors. 2025 [accessed 2025 Nov 4]. https:\/\/www.prnewswire.com\/news-releases\/novo-nordisk-submits-biologics-license-application-bla-to-fda-for-mim8-an-investigational-prophylaxis-treatment-for-people-living-with-hemophilia-a-with-or-without-inhibitors-302568867.html."},{"key":"e_1_3_4_71_1","unstructured":"Novo Nordisk. Novo Nordisk\u2019s sales increased by 12% in Danish kroner and by 15% at CER in the first nine months of 2025; R&D pipeline progress continues. 2025 [accessed 2025 Nov 5]. https:\/\/www.novonordisk-us.com\/media\/news-archive\/news-details.html?id=916446."},{"key":"e_1_3_4_72_1","unstructured":"AstraZeneca. AstraZeneca\u2019s 9M and Q3 2025 financial results. 2025 [accessed 2025 Dec 5]. https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/2025\/9m-q3\/9M-and-Q3-2025-results-announcement.pdf."},{"key":"e_1_3_4_73_1","unstructured":"AstraZeneca. Gefurulimab dual-binding nanobody demonstrated statistically significant and clinically meaningful improvement in functional activities of daily living in adults with generalised myasthenia gravis in PREVAIL Phase III trial. 2025 [accessed 2025 Nov 4]. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2025\/gefurulimab-nanobody-met-phase-iii-endpoints.html."},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2585616"},{"key":"e_1_3_4_75_1","unstructured":"Viridian Therapeutics Inc. Viridian Therapeutics announces BLA acceptance and priority review for veligrotug for the treatment of thyroid eye disease. 2025 [accessed 2025 Dec 22]. https:\/\/investors.viridiantherapeutics.com\/news\/news-details\/2025\/Viridian-Therapeutics-Announces-BLA-Acceptance-and-Priority-Review-for-Veligrotug-for-the-Treatment-of-Thyroid-Eye-Disease\/default.aspx."},{"key":"e_1_3_4_76_1","unstructured":"Viridian Therapeutics Inc.. Viridian corporate presentation. 2025 [Accessed 2025 Oct 31]. https:\/\/s203.q4cdn.com\/807813999\/files\/doc_presentations\/2025\/Oct\/21\/VRDN-October-2025-Corp-Deck.pdf."},{"key":"e_1_3_4_77_1","unstructured":"Viridian Therapeutics Inc. Viridian Therapeutics announces positive long-term durability data from the VELIGROTUG Phase 3 THRIVE clinical trial in patients with active thyroid eye disease (TED). 2025 [accessed 2025 Oct 31]. https:\/\/investors.viridiantherapeutics.com\/news\/news-details\/2025\/Viridian-Therapeutics-Announces-Positive-Long-Term-Durability-Data-from-the-Veligrotug-Phase-3-THRIVE-Clinical-Trial-in-Patients-with-Active-Thyroid-Eye-Disease-TED\/default.aspx."},{"key":"e_1_3_4_78_1","unstructured":"Viridian Therapeutics Inc. Viridian Therapeutics announces positive topline results from VELIGROTUG Phase 3 THRIVE-2 clinical trial in patients with chronic thyroid eye disease. 2024 [accessed 2025 Oct 31]. https:\/\/s203.q4cdn.com\/807813999\/files\/doc_news\/Viridian-Therapeutics-Announces-Positive-Topline-Results-from-Veligrotug-Phase-3-THRIVE-2-Clinical-Trial-in-Patients-with-Chronic-Thy-3CV7K.pdf."},{"key":"e_1_3_4_79_1","unstructured":"Vanda Pharmaceuticals Inc. Vanda announces submission of biologics license application to the FDA for imsidolimab for the treatment of generalized pustular psoriasis. 2025 [accessed 2025 Dec 27]. https:\/\/vandapharmaceuticalsinc.gcs-web.com\/node\/16676\/pdf."},{"issue":"8","key":"e_1_3_4_80_1","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1016\/j.jid.2025.06.1571","article-title":"Imsidolimab, a novel IgG4 IL36 receptor antagonist, was effective and well tolerated in patients with GPP","volume":"145","author":"Smieszek SP","year":"2025","unstructured":"Smieszek SP. Imsidolimab, a novel IgG4 IL36 receptor antagonist, was effective and well tolerated in patients with GPP. J Invest Dermatol. 2025;145(8):S206. https:\/\/www.jidonline.org\/article\/S0022-202X(25)02200-6\/fulltext.","journal-title":"J Invest Dermatol"},{"key":"e_1_3_4_81_1","unstructured":"Vanda Pharmaceuticals Inc. Vanda Pharmaceuticals and Anaptys announce exclusive global license agreement for Vanda to develop and commercialize imsidolimab an IL-36R antagonist. 2025 [accessed 2025 Nov 19]. https:\/\/vandapharmaceuticalsinc.gcs-web.com\/node\/16241\/pdf."},{"key":"e_1_3_4_82_1","unstructured":"Harbour BioMed. Harbour BioMed reports 2025 interim results. 2025 [accessed 2025 Oct 31]. https:\/\/www.harbourbiomed.com\/news\/248.html."},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.0044"},{"key":"e_1_3_4_84_1","unstructured":"Biopharma H. HanAll Biopharma announces orphan drug designation for batoclimab in Japan for active thyroid eye disease. 2025 [accessed 2025 Oct 21]. https:\/\/www.hanall.com\/board_view.php?bo_table=press&idx=101."},{"key":"e_1_3_4_85_1","unstructured":"Sunshine Guojian Pharmaceutical Co Inc. Semi-annual report [Chinese]. 2025. accessed 2025 Oct 17. https:\/\/static.sse.com.cn\/disclosure\/listedinfo\/announcement\/c\/new\/2025-08-30\/688336_20250830_A3C5.pdf."},{"key":"e_1_3_4_86_1","unstructured":"Sunshine Guojian Pharmaceutical Co Inc. The phase III clinical trial of SSGJ-608 injection for the treatment of moderate to severe plaque psoriasis achieved all efficacy endpoints [Chinese]. 2024 [accessed 2025 Oct 17]. https:\/\/static.sse.com.cn\/disclosure\/listedinfo\/announcement\/c\/new\/2024-08-10\/688336_20240810_86RA.pdf."},{"key":"e_1_3_4_87_1","unstructured":"Akeso Inc. First half report. 2025 [accessed 2025 Oct 16]. https:\/\/www.akesobio.com\/media\/2656\/akeso-2025-h1-english-final.pdf."},{"key":"e_1_3_4_88_1","unstructured":"Akeso Biopharma Co. Ltd.. Akeso released complete Phase 3 data for gumokimab (AK111 IL-17) in moderate to severe plaque psoriasis. 2024 [accessed 2025 Oct 16]. https:\/\/www.akesobio.com\/en\/media\/akeso-news\/241028\/."},{"key":"e_1_3_4_89_1","unstructured":"Akeso Biopharma Co. Ltd.. Akeso reports phase 3 trials show positive results: gumokimab (IL-17) for ankylosing spondylitis and manfidokimab (IL-4R\u03b1) for atopic dermatitis achieve primary endpoints. 2025 [accessed 2025 Oct 16]. https:\/\/www.akesobio.com\/en\/media\/akeso-news\/250825\/."},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29016"},{"key":"e_1_3_4_91_1","unstructured":"China Medical System Holdings Limited.. China Medical System (867.HK; 8A8.SG) signed collaboration agreements for two innovative biologics used for passive immunization against tetanus and rabies. 2025 [accessed 2025 Oct 30]. https:\/\/www.globenewswire.com\/news-release\/2025\/09\/23\/3154384\/0\/en\/China-Medical-System-867-HK-8A8-SG-Signed-Collaboration-Agreements-for-Two-Innovative-Biologics-Used-for-Passive-Immunization-Against-Tetanus-and-Rabies.html."},{"key":"e_1_3_4_92_1","unstructured":"Genrix (Shanghai). Biopharmaceutical Co. Ltd. Voluntary disclosure of the new drug application for GR2001 injection announcement of Acceptance [Chinese]. 2025 [accessed 2025 Oct 8]. https:\/\/static.sse.com.cn\/disclosure\/listedinfo\/announcement\/c\/new\/2025-05-23\/688443_20250523_M0NU.pdf."},{"key":"e_1_3_4_93_1","unstructured":"Beijing Tianguangshi Biotechnology Co. Announcement regarding the acceptance of the new drug application for its core product MIL62. 2025 [accessed 2025 Oct 9]. https:\/\/pdf.dfcfw.com\/pdf\/H2_AN202505261679503982_1.pdf?1748277899000.pdf."},{"key":"e_1_3_4_94_1","unstructured":"PhIRDA. The second potential first! Tianguangshi\u2019s CD20 antibody has been approved for marketing approval for the treatment of primary membranous nephropathy. 2025 [accessed 2025 Oct 10]. https:\/\/www.phirda.com\/artilce_40447.html?module=trackingCodeGenerator."},{"key":"e_1_3_4_95_1","volume-title":"Presented at: 2025 ECTRIMS Congress; September 24-26; Barcelona, Spain","author":"Huang D","unstructured":"Huang D, Wu L, Chen J. Type ii anti-CD20 antibody MIL62 in AQP4-positive neuromyelitis optica spectrum disorder: a multicenter, randomized, double-blind, phase III trial. Presented at: 2025 ECTRIMS Congress; September 24-26; Barcelona, Spain; https:\/\/conferences.medicom-publishers.com\/specialisation\/neurology\/ectrims-2025\/novel-anti-cd20-antibody-shows-efficacy-in-aqp4-igg-positive-nmosd\/."},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.202564sha3em"},{"key":"e_1_3_4_97_1","unstructured":"3SBio. The marketing application of 3SBio\u2019s anti-IL-1\u03b2 monoclonal antibody SSGJ-613\u00a0has been accepted by the National Medical Products Administration. 2025 [accessed 2025 Nov 12]. https:\/\/www.3s-guojian.com\/news\/details\/231.html."},{"key":"e_1_3_4_98_1","unstructured":"Connect Biopharma Holdings Ltd. Corporate presentation September 2025. [accessed 2025 Oct 14]. https:\/\/investors.connectbiopharma.com\/static-files\/6e87b037-f42b-40b6-a811-e577db819e4b."},{"key":"e_1_3_4_99_1","unstructured":"Connect Biopharma Holdings Ltd. Connect Biopharma\u2019s exclusive licensee in China Simcere Pharmaceutical announced submission of its new drug application for rademikibart for the treatment of atopic dermatitis in China. 2025 [accessed 2025 Oct 11]. https:\/\/investors.connectbiopharma.com\/news-releases\/news-release-details\/connect-biopharmas-exclusive-licensee-china-simcere."},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.11.924"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf347"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202409-1708OC"},{"key":"e_1_3_4_103_1","unstructured":"Chongqing Genrix Biopharmaceutical. The marketing application for Zhixiang Jintai GR1802 injection for moderate to severe atopic dermatitis has been accepted [Chinese]. 2025 [accessed 2025 Nov 11]. https:\/\/genrixbio.com\/#\/article_details?id=83."},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1155\/dth\/6903760"},{"key":"e_1_3_4_105_1","unstructured":"Huabo Biopharm (Shanghai). The marketing application of HB0034 the first domestically developed IL-36R monoclonal antibody has been accepted. 2025 [accessed 2025 Nov 14]. https:\/\/www.huabobio.com\/newsshow\/249.html."},{"key":"e_1_3_4_106_1","unstructured":"Salubris Pharmaceuticals Ltd. Salubris\u2019 SAL003 BLA accepted by NMPA for lipid-lowering therapy. 2025 [accessed 2025 Nov 13]. https:\/\/www.linkedin.com\/posts\/salubris-pharmaceuticals_salubrispharma-pipelinemilestone-biologicinnovation-activity-7380932319768891392-V4OC."},{"key":"e_1_3_4_107_1","unstructured":"China Medical System Holdings Limited. Cms (867.HK; 8A8.SG) NDA for AD indication of long-acting anti-IL-4R\u03b1 humanized monoclonal antibody injection MG-K10 accepted in China. 2025 [accessed 2025 Nov 4]. https:\/\/www.globenewswire.com\/news-release\/2025\/10\/30\/3177285\/0\/en\/CMS-867-HK-8A8-SG-NDA-for-AD-Indication-of-Long-acting-Anti-IL-4R\u03b1-Humanized-Monoclonal-Antibody-Injection-MG-K10-Accepted-in-China.html."},{"key":"e_1_3_4_108_1","unstructured":"Hunan Mabgeek Biotechnology Co. Ltd. MabGeek biotech receives approval notice for phase III clinical trial of chronic spontaneous urticaria (CSU). 2025 [accessed 2025 Nov 4]. https:\/\/www.mabgeek.com\/index.php?c=show&id=39."},{"key":"e_1_3_4_109_1","unstructured":"Shanghai Junshi Biosciences Co. Ltd. Junshi Biosciences announces acceptance of the NDA for Roconkibart (IL-17A) for the treatment of moderate to severe plaque psoriasis. 2025 [accessed 2025 Dec 5]. https:\/\/www.globenewswire.com\/news-release\/2025\/12\/05\/3200830\/0\/en\/Junshi-Biosciences-Announces-Acceptance-of-the-NDA-for-Roconkibart-IL-17A-for-the-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis.html."},{"key":"e_1_3_4_110_1","unstructured":"Shanghai Junshi Biosciences Co. Ltd. Junshi Biosciences announces the Phase 3 study of JS005 (IL-17A) for the treatment of moderate to severe plaque psoriasis met primary endpoints. 2025 [accessed 2025 Sep 23]. https:\/\/www.globenewswire.com\/news-release\/2025\/09\/07\/3145717\/0\/en\/Junshi-Biosciences-Announces-the-Phase-3-Study-of-JS005-IL-17A-for-the-Treatment-of-Moderate-to-Severe-Plaque-Psoriasis-Met-Primary-Endpoints.html."},{"key":"e_1_3_4_111_1","unstructured":"Livzon Pharmaceutical Group Inc. Marketing authorization application for Lecankitug injection accepted for review by China\u2019s National Medical Products Administration. 2025 [accessed 2025 Dec 27]. https:\/\/www.hkexnews.hk\/listedco\/listconews\/sehk\/2025\/1224\/2025122400984.pdf."},{"key":"e_1_3_4_112_1","unstructured":"Livzon Pharmaceutical Group Inc. Achievement of the primary endpoint in phase III clinical trial of recombinant anti-human IL-17A\/F humanized monoclonal antibody injection. 2025 [accessed 2025 Dec 24]. https:\/\/www.hkexnews.hk\/listedco\/listconews\/sehk\/2025\/0721\/2025072101082.pdf."},{"key":"e_1_3_4_113_1","unstructured":"Bio-Thera Solutions Ltd.. The marketing authorization application for Bio-thera\u2019s BAT5906 (a recombinant anti-VEGF humanized monoclonal antibody) (nAMD) has been accepted by the NMPA. 2025 [accessed 2025 Dec 27]. https:\/\/www.bio-thera.com\/col_24\/1337.html."},{"key":"e_1_3_4_114_1","unstructured":"Bio-Thera Solutions Ltd.. Bio-thera Solutions announced positive results from its pivotal Phase III registration clinical trial of BAT5906 (a recombinant anti-VEGF humanized monoclonal antibody) targeting wAMD. 2025 [accessed 2025 Dec 27]. https:\/\/www.bio-thera.com\/col_24\/1189.html."},{"key":"e_1_3_4_115_1","doi-asserted-by":"crossref","unstructured":"Pfizer. Second quarter 2025 earnings teleconference. 2025 [accessed 2025 Oct 9]. https:\/\/s206.q4cdn.com\/795948973\/files\/doc_financials\/2025\/q2\/Q2-2025-Earnings-Charts-FINAL.pdf.","DOI":"10.1016\/j.fopow.2025.10.019"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03738-z"},{"key":"e_1_3_4_117_1","unstructured":"AbbVie. AbbVie submits biologics license application (BLA) to U.S. FDA for Pivekimab sunirine (PVEK) an investigational antibody-drug conjugate (ADC) to treat rare cancer with limited treatment options. 2025 [accessed 2025 Oct 14]. https:\/\/news.abbvie.com\/2025-09-30-AbbVie-Submits-Biologics-License-Application-BLA-to-U-S-FDA-for-Pivekimab-sunirine-PVEK-an-Investigational-Antibody-Drug-Conjugate-ADC-to-Treat-Rare-Cancer-with-Limited-Treatment-Options."},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.6502"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00674-5"},{"key":"e_1_3_4_120_1","unstructured":"Jiangsu HengRui Pharmaceuticals Co. Ltd. Management presentation. 2025 [accessed 2025 Oct 9]. https:\/\/www.hengrui.com\/images\/investor\/\u6295\u8d44\u8005\u63a8\u4ecb\u6750\u6599-\u82f1\u6587.pdf."},{"issue":"2","key":"e_1_3_4_121_1","doi-asserted-by":"crossref","first-page":"S1250","DOI":"10.1016\/j.annonc.2024.08.2302","article-title":"Lba60 phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric\/gastroesophageal junction adenocarcinoma (G\/GEJA)","volume":"35","author":"Peng Z","year":"2024","unstructured":"Peng Z, Wang J, Zhang Y, Li H, Zhao Q, Zhu X, Wei S, Cheng Y, Yang W, Yao J, et al. Lba60 phase III study of SHR-1701 versus placebo in combination with chemo as first-line (1L) therapy for HER2-negative gastric\/gastroesophageal junction adenocarcinoma (G\/GEJA). Ann Oncol. 2024;35(2):S1250. https:\/\/www.annalsofoncology.org\/article\/S0923-7534(24)03882-1\/fulltext.","journal-title":"Ann Oncol"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17558"},{"key":"e_1_3_4_123_1","unstructured":"Alphamab Oncology. The new drug application for KN026 (anbenitamab injection) has been accepted by the National Medical Products Administration. 2025 [accessed 2025 Oct 21]. https:\/\/www.alphamabonc.com\/en\/html\/news\/2708.html."},{"key":"e_1_3_4_124_1","unstructured":"Alphamab Oncology. Research updates on a Phase III clinical trial of anbenitamab (KN026) presented at ESMO Congress 2025 LBA oral presentation session. 2025 [accessed 2025 Nov 11]. https:\/\/www.alphamabonc.com\/en\/html\/news\/2719.html."},{"key":"e_1_3_4_125_1","unstructured":"SystImmune Inc.. SystImmune to receive milestone payment from Bristol Myers Squibb under Iza-Bren collaboration. 2025 [accessed 2025 Dec 10]. https:\/\/systimmune.com\/news\u2014systimmune-to-receive-milestone-payment-from-bristol-myers-squibb-under-iza-bren-collaboration."},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)01954-3"},{"key":"e_1_3_4_127_1","unstructured":"Regeneron Pharmaceuticals Inc. Regeneron announces positive Phase 3 trial in adults with ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP) demonstrating that garetosmab prevents greater than 99% of abnormal bone formation. 2025 [accessed 2025 Sep 23]. https:\/\/investor.regeneron.com\/news-releases\/news-release-details\/regeneron-announces-positive-phase-3-trial-adults-ultra-rare."},{"key":"e_1_3_4_128_1","unstructured":"Dyne Therapeutics Inc. Dyne therapeutics announces positive topline results from Phase 1\/2 DELIVER trial of Z-Rostudirsen in Duchenne muscular dystrophy (DMD). 2025 [accessed 2025 Dec 23]. https:\/\/investors.dyne-tx.com\/news-releases\/news-release-details\/dyne-therapeutics-announces-fda-breakthrough-therapy-0."},{"key":"e_1_3_4_129_1","unstructured":"Dyne Therapeutics Inc. Dyne Therapeutics announces new long-term clinical data from Phase 1\/2 DELIVER trial of DYNE-251 in Duchenne muscular dystrophy. 2025 [accessed 2025 Oct 14]. https:\/\/investors.dyne-tx.com\/news-releases\/news-release-details\/dyne-therapeutics-announces-new-long-term-clinical-data-phase-12."},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkaf241"},{"key":"e_1_3_4_131_1","unstructured":"Avidity Biosciences Inc. Avidity Biosciences announces positive preBLA meeting with U.S. FDA for delzota in DMD44 with a submission planned for Q1 2026. 2025 [accessed 2025 Oct 22]. https:\/\/investors.aviditybiosciences.com\/2025-10-13-Avidity-Biosciences-Announces-Positive-Pre-BLA-Meeting-with-U-S-FDA-for-del-zota-in-DMD44-with-a-Submission-Planned-for-Q1-2026."},{"key":"e_1_3_4_132_1","unstructured":"Avidity Biosciences Inc. Avidity Biosciences enters into agreement to be acquired by Novartis AG. 2025 [accessed 2025 Nov 3]. https:\/\/investors.aviditybiosciences.com\/2025-10-26-Avidity-Biosciences-Enters-into-Agreement-to-be-Acquired-by-Novartis-AG."},{"key":"e_1_3_4_133_1","unstructured":"Avidity Biosciences Inc. Avidity Biosciences: Delzota demonstrated reversal of disease progression across key functional endpoints in EXPLORE44R and EXPLORE44OLE\u2122 Phase 1\/2 trial in people living with DMD44. 2025 [accessed 2025 Oct 22]. https:\/\/investors.aviditybiosciences.com\/2025-09-10-Avidity-Biosciences-Del-zota-Demonstrated-Reversal-of-Disease-Progression-Across-Key-Functional-Endpoints-in-EXPLORE44-R-and-EXPLORE44-OLE-TM-Phase-1-2-Trial-in-People-Living-with-DMD44."},{"key":"e_1_3_4_134_1","unstructured":"Novartis International AG. Novartis ianalumab first drug to reduce disease activity and patient burden in Sj\u00f6gren\u2019s disease phase III trials. 2025 [accessed 2025 Dec 3]. https:\/\/www.novartis.com\/news\/media-releases\/novartis-ianalumab-first-drug-reduce-disease-activity-and-patient-burden-sjogrens-disease-phase-iii-trials."},{"key":"e_1_3_4_135_1","unstructured":"Grader-Beck T Mariette X Finzel S Schiopu E Papas A Devauchelle-Pensec V D\u00f6rner T Sopala M Zeng X Noaiseh G et al. Ianalumab demonstrates significant reduction in disease activity in patients with Sjogren\u2019s disease: efficacy and safety results from two global phase 3 randomized placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2). Presented at the American College of Rheumatology (ACR) Congress. [October 24-29 2025; Chicago (IL). https:\/\/acrabstracts.org\/abstract\/ianalumab-demonstrates-significant-reduction-in-disease-activity-in-patients-with-sjogrens-disease-efficacy-and-safety-results-from-two-global-phase-3-randomized-placebo-controlled-double-blind-s\/"},{"key":"e_1_3_4_136_1","unstructured":"An nexon Inc. An Nexon reports third quarter 2025 financial results portfolio progress and key anticipated milestones. 2025. [accessed 2025 Dec 3]. https:\/\/ir.annexonbio.com\/news-releases\/news-release-details\/annexon-reports-third-quarter-2025-financial-results-portfolio."},{"key":"e_1_3_4_137_1","volume-title":"Presentation at The American Academy Of Neurology Annual Meeting","author":"Johnson N","unstructured":"Johnson N, Day J, Hamel J, Thornton C, Subramony SH, Payam Soltanzadeh P, Statland J, Freimer M, Quan D, Knisely B, et al. Gbs-02: a phase 3 study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of ANX005 in patients with guillain-barr\u00e9 syndrome (GBS). Presentation at The American Academy Of Neurology Annual Meeting; April 5-9, 2025; [accessed April 5-9] 2025; San Diego (CA). https:\/\/annexonbio.com\/wp-content\/uploads\/2025\/04\/AAN-GBS-02-Study-Encore-Presentation_Final.pdf"},{"key":"e_1_3_4_138_1","unstructured":"Zenas BioPharma Inc. Transformational global collaboration with InnoCare Pharma. 2025 [accessed 2025 Oct 22]. https:\/\/investors.zenasbio.com\/static-files\/68b70f32-04ae-4c55-ab00-40625788c8d8."},{"key":"e_1_3_4_139_1","unstructured":"Zenas BioPharma Inc. Zenas BioPharma announces positive results from Phase 2 Moonstone trial of obexelimab in relapsing multiple sclerosis. 2025 [accessed 2025 Nov 2]. https:\/\/investors.zenasbio.com\/news-releases\/news-release-details\/zenas-biopharma-announces-positive-results-phase-2-moonstone."},{"key":"e_1_3_4_140_1","unstructured":"Avidity Biosciences Inc. Avidity Biosciences reports third quarter 2025 financial results and recent highlights. 2025. [accessed 2025 Dec 3]. https:\/\/investors.aviditybiosciences.com\/2025-11-10-Avidity-Biosciences-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Highlights."},{"key":"e_1_3_4_141_1","volume-title":"Muscular Dystrophy Association Clinical & Scientific Conference, Orlando, FL","author":"Avidity Biosciences, Inc","year":"2024","unstructured":"Avidity Biosciences, Inc. Initial results of the Phase 2 openlabel extension study of AOC 1001 in adults with myotonic dystrophy type 1: MARINAOLE\u2122. Muscular Dystrophy Association Clinical & Scientific Conference, Orlando, FL; 2024. [accessed 2025 Oct 22]. https:\/\/www.aviditybiosciences.com\/sites\/default\/files\/2025-04\/MDA-2024-MARINA-OLE-DM1_v6.0_STC.pdf."},{"key":"e_1_3_4_142_1","unstructured":"Kodiak Sciences Inc. Corporate Presentation. 2025 [accessed 2025 Dec 3]. https:\/\/ir.kodiak.com\/static-files\/bdef019c-988b-4c2b-a70c-c8bf8f74578d."},{"issue":"7","key":"e_1_3_4_143_1","first-page":"1773","article-title":"Tarcocimab tedromer (KSI-301) 5mg: outcomes of the phase 3 GLOW study in patients with non-proliferative diabetic retinopathy","volume":"65","author":"Wong RW","year":"2024","unstructured":"Wong RW, Janer D, Zawadzki R, Perlroth DV, Velazquez-Martin P. Tarcocimab tedromer (KSI-301) 5mg: outcomes of the phase 3 GLOW study in patients with non-proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2024;65(7):1773. https:\/\/iovs.arvojournals.org\/article.aspx?articleid=2794551.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_4_144_1","unstructured":"MedPath. Ksi-301 advanced drug monograph: clinical and strategic analysis. [accessed 2025 Oct 20]. https:\/\/trial.medpath.com\/drug\/report\/93b7968fc594f76a."},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36642-y"},{"key":"e_1_3_4_146_1","unstructured":"AstraZeneca. Clinical trials appendix: Q3 2025 results update. 2025 [accessed 2025 Dec 5]. https:\/\/www.astrazeneca.com\/content\/dam\/az\/PDF\/2025\/9m-q3\/9M-and-Q3-2025-results-clinical-trials-appendix.pdf."},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02231-2024"},{"key":"e_1_3_4_148_1","unstructured":"Rezolute Inc.. A late-stage rare disease company treating hyperinsulinism. 2025 [accessed 2025 Nov 8]. https:\/\/ir.rezolutebio.com\/_assets\/_66887b51f090e11fb8fad4eb8fb4fbef\/rezolutebio\/db\/693\/10050\/pdf\/RZLT+Corporate+Presentation\u00b1+November+2025_New+Template.pdf."},{"key":"e_1_3_4_149_1","unstructured":"Rezolute Inc.. Rezolute reports first quarter fiscal 2026 financial results and provides business update. 2025. accessed Nov 8. https:\/\/ir.rezolutebio.com\/news\/detail\/366\/rezolute-reports-first-quarter-fiscal-2026-financial-results-and-provides-business-update."},{"key":"e_1_3_4_150_1","unstructured":"Qyuns Therapeutics Co. Ltd. Interim report. 2025 [accessed 2025 Sep 26]. https:\/\/www.qyuns.net\/upload\/en\/file\/2025-09\/col274\/1758292342833.pdf."},{"key":"e_1_3_4_151_1","unstructured":"Qyuns Therapeutics Co. Ltd. Phase III clinical trial of Qx002N for ankylosing spondylitis reaches primary endpoint. 2025 [accessed 2025 Sep 26]. https:\/\/www.qyuns.net\/upload\/en\/file\/2025-02\/col274\/1740402398319.pdf."},{"key":"e_1_3_4_152_1","unstructured":"Qyuns Therapeutics Co. Ltd. Interim results 2025. 2025 [accessed 2025 Sep 28]. https:\/\/www.qyuns.net\/upload\/en\/file\/2025-09\/col232\/1758017205581.pdf."},{"key":"e_1_3_4_153_1","unstructured":"LongBio Pharma (Suzhou) Co. Ltd.. Application proof of LongBio Pharma (Suzhou) Co. Ltd. [Accessed 2025 Nov 2]. https:\/\/www1.hkexnews.hk\/app\/sehk\/2025\/107640\/documents\/sehk25082101308.pdf."},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.70074"},{"key":"e_1_3_4_155_1","unstructured":"Viridian Therapeutics Inc. Viridian Therapeutics announces completion of enrollment in both REVEAL clinical trials and positive portfolio updates. 2025 [accessed 2025 Oct 31]. https:\/\/s203.q4cdn.com\/807813999\/files\/doc_news\/Viridian-Therapeutics-Announces-Completion-of-Enrollment-in-both-REVEAL-Clinical-Trials-and-Positive-Portfolio-Updates-2025.pdf."},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae090.112"},{"key":"e_1_3_4_157_1","unstructured":"Moomoo Technologies Inc. Pacific Securities maintains a \u2018buy\u2019 rating for 3SBio Inc. (01530) citing its steady performance and abundant catalysts. 2025 [accessed 2025 Nov 1]. https:\/\/www.moomoo.com\/news\/post\/58770421\/broker-focus-pacific-securities-maintains-a-buy-rating-for-3sbio?level=1&data_ticket=1751304958912009."},{"key":"e_1_3_4_158_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01368-4"},{"key":"e_1_3_4_159_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-023-01010-1"},{"key":"e_1_3_4_160_1","unstructured":"Akeso Biopharma. Safety pharmacokinetics pharmacodynamics and efficacy of AK120 in participants with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled phase II clinical trial. 2025 Sep 17-20 EADV Congress Abst 66. [accessed 2025 Oct 18]. https:\/\/s3.eu-central-1.amazonaws.com\/m-anage.com.storage.eadv\/abstracts_congress_2025\/52111.pdf."},{"key":"e_1_3_4_161_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0974"},{"key":"e_1_3_4_162_1","unstructured":"Inhibrx Biosciences Inc. Inhibrx Biosciences reports positive topline results from its registrational trial of ozekibart (INBRX-109) in chondrosarcoma and provides updates on colorectal cancer and Ewing sarcoma expansion cohorts. 2025. [accessed 2025 Oct 29]. https:\/\/inhibrxbiosciences.investorroom.com\/2025-10-23-Inhibrx-Biosciences-Reports-Positive-Topline-Results-from-its-Registrational-Trial-of-Ozekibart-INBRX-109-in-Chondrosarcoma-and-Provides-Updates-on-Colorectal-Cancer-and-Ewing-Sarcoma-Expansion-Cohorts."},{"key":"e_1_3_4_163_1","unstructured":"AstraZeneca. License agreement with KYM Biosciences for CMG901 a Claudin-18.2 antibody drug conjugate completed. 2023 [accessed 2024 Sep 2]. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/astrazeneca-completes-agreement-with-kym-for-cmg901.html#."},{"key":"e_1_3_4_164_1","unstructured":"BioNTech. BioNTech announces third quarter 2025 financial results and corporate update. 2025 [accessed 2025 Nov 4]. https:\/\/investors.biontech.de\/news-releases\/news-release-details\/biontech-announces-third-quarter-2025-financial-results-and."},{"key":"e_1_3_4_165_1","unstructured":"BioNTech. BioNTech and DualityBio announce phase 3 trial of ADC candidate BNT323\/DB-1303 met primary endpoint of progression free survival in HER2-positive metastatic or unresectable breast cancer. 2025 [accessed 2025 Nov 5]. https:\/\/investors.biontech.de\/news-releases\/news-release-details\/biontech-and-dualitybio-announce-phase-3-trial-adc-candidate."},{"key":"e_1_3_4_166_1","unstructured":"Daiichi Sankyo. Ifinatamab deruxtecan demonstrated clinically meaningful response rates in patients with extensive-stage small cell lung cancer in IDeate-Lung01 Phase 2 trial. 2025 [accessed 2025 Sep 23]. https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/202509\/20250907_E.pdf."},{"key":"e_1_3_4_167_1","unstructured":"Fierce Biotech. Patient deaths prompt partial hold for Daiichi-Merck\u2019s global phase 3 ADC program. 2025 [accessed 2025 Dec 19]. https:\/\/www.fiercebiotech.com\/biotech\/patient-deaths-prompt-partial-hold-daiichi-mercks-global-phase-3-adc-program."},{"key":"e_1_3_4_168_1","unstructured":"Merus NV. Genmab to acquire Merus expanding late-stage pipeline and accelerating into a wholly owned model. 2025 [accessed 2025 Sep 29]. https:\/\/ir.merus.nl\/news-releases\/news-release-details\/genmab-acquire-merus-expanding-late-stage-pipeline-and."},{"issue":"16","key":"e_1_3_4_169_1","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1200\/JCO.2025.43.16_suppl.6024","article-title":"Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent\/metastatic (r\/m) head and neck squamous cell carcinoma (HNSCC): phase 2 trial","volume":"43","author":"van Herpen CML","year":"2025","unstructured":"van Herpen CML, Daste A, Arrazubi V, De Boer JP, Rojas KI, Clatot F, Fontana E, Harandi A, Hellyer J, Hollebecque A, et al. Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent\/metastatic (r\/m) head and neck squamous cell carcinoma (HNSCC): phase 2 trial. J Clin Oncol. 2025;43(16_suppl):6024\u20136024. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2025.43.16_suppl.6024.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_170_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2511470"},{"key":"e_1_3_4_171_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2498162"},{"key":"e_1_3_4_172_1","unstructured":"Taylor & Francis. Artificial intelligence and machine learning in antibody development. mAbs. 2025 [accessed 2025 Nov 18]. https:\/\/www.tandfonline.com\/journals\/kmab20\/collections\/ai-ml-antibody-development."}],"container-title":["mAbs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/19420862.2026.2614669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:07:44Z","timestamp":1768986464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/19420862.2026.2614669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":172,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12,31]]}},"alternative-id":["10.1080\/19420862.2026.2614669"],"URL":"https:\/\/doi.org\/10.1080\/19420862.2026.2614669","relation":{},"ISSN":["1942-0862","1942-0870"],"issn-type":[{"value":"1942-0862","type":"print"},{"value":"1942-0870","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=kmab20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-01-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-01","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2614669"}}